China Resources Pharmaceutical Group's Subsidiary Expects Higher Attributable Profit in 2024

MT Newswires Live

2025/01/22

China Resources Pharmaceutical Group (HKG:3320) subsidiary China Resources Boya Bio-pharmaceutical Group (SHE:300294) expects to record net profit attributable to the shareholders between 380.00 million yuan and 480.00 million yuan in 2024, higher than 237.5 million yuan logged for the preceding year, a Wednesday Hong Kong bourse filing said.

China Resources Boya Bio-pharmaceutical Group attributed the increase in expected profit to a rise in revenue from its blood products and the impact of non-recurring gains and losses on its net profit during the reporting period.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2505716296"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505716296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505716296?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-22 17:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505716296","market":"hk","top_or_hot":-1,"title":"China Resources Pharmaceutical Group's Subsidiary Expects Higher Attributable Profit in 2024","media":"MT Newswires Live","content":"<html><body><p> China Resources Pharmaceutical Group (HKG:3320) subsidiary China Resources Boya Bio-pharmaceutical Group (SHE:300294) expects to record net profit attributable to the shareholders between 380.00 million yuan and 480.00 million yuan in 2024, higher than 237.5 million yuan logged for the preceding year, a Wednesday Hong Kong bourse filing said.</p><p>China Resources Boya Bio-pharmaceutical Group attributed the increase in expected profit to a rise in revenue from its blood products and the impact of non-recurring gains and losses on its net profit during the reporting period.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharmaceutical Group's Subsidiary Expects Higher Attributable Profit in 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharmaceutical Group's Subsidiary Expects Higher Attributable Profit in 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-22 17:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China Resources Pharmaceutical Group (HKG:3320) subsidiary China Resources Boya Bio-pharmaceutical Group (SHE:300294) expects to record net profit attributable to the shareholders between 380.00 million yuan and 480.00 million yuan in 2024, higher than 237.5 million yuan logged for the preceding year, a Wednesday Hong Kong bourse filing said.</p><p>China Resources Boya Bio-pharmaceutical Group attributed the increase in expected profit to a rise in revenue from its blood products and the impact of non-recurring gains and losses on its net profit during the reporting period.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505716296","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505716296","pubTimestamp":1737539831,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China Resources Pharmaceutical Group  subsidiary China Resources Boya Bio-pharmaceutical Group  expects to record net profit attributable to the shareholders between 380.00 million yuan and 480.00 million yuan in 2024, higher than 237.5 million yuan logged for the preceding year, a Wednesday Hong Kong bourse filing said.China Resources Boya Bio-pharmaceutical Group attributed the increase in expected profit to a rise in revenue from its blood products and the impact of non-recurring gains and losses on its net profit during the reporting period.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300294":"博雅生物","BK1191":"制药","BK0197":"中小创蓝筹","03320":"华润医药","BK1570":"华润系","BK0239":"医药制造","BK0046":"生物疫苗"},"translate_title":"华润医药集团子公司预计2024年归属利润较高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300294":0.9,"03320":0.9},"content_text":"China Resources Pharmaceutical Group (HKG:3320) subsidiary China Resources Boya Bio-pharmaceutical Group (SHE:300294) expects to record net profit attributable to the shareholders between 380.00 million yuan and 480.00 million yuan in 2024, higher than 237.5 million yuan logged for the preceding year, a Wednesday Hong Kong bourse filing said.China Resources Boya Bio-pharmaceutical Group attributed the increase in expected profit to a rise in revenue from its blood products and the impact of non-recurring gains and losses on its net profit during the reporting period.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}